Iodine 1% in Industrial methylated spirit 70% solution
Requires a prescription from a doctor or prescriber
Used as an antiseptic and a means of treating and preventing iodine deficiency
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 16 studies.
Reviews & meta-analyses: 1 · 1966–2025
Showing all 16 studies, sorted by most relevant.
Juan de Dios Azorín Abraham, Guillermo Torrado Durán, Norma Sofía Torres Pabón, et al.
Saudi Pharmaceutical Journal : SPJ, 2023
Objectives: Potassium iodide (KI) is a treatment to neutralize radioactive agents that could be inhaled or ingested in nuclear incidents. The inorganic salt KI constitutes a source of iodine, which in the body acts by accumulating in the thyroid gland, producing its saturation, and thus preventing the fixation of radioactive iodine species. In Spain, the Military Defence Pharmacy Centre (CEMILFARDEF) was challenged to develop this antidote to be distributed among the population surrounding nuclear power plants, in only one new solid pharmaceutical form for oral administration, in order to replace the two pharmaceutical forms available, which are capsules for adults and oral solution for children, considered less versatile. Methods: A selection of excipients was carried out to achieve pharmacotechnical behaviour suitable for the industrial manufacture of potassium iodide in tablets, complying with the pre-established process and finished product quality parameters. The development allowed the preparation of three industrial-sized batches on which the stability of the developed formulation was studied. Results: An uncoated 65 mg double-scored potassium iodide tablet was developed using easily accessible excipients in the formulation and direct compression as the manufacturing method. The formula complied with the stability tests, with which the development carried out can respond to the eventual demand that its elaboration would entail in the event of nuclear incidents. Conclusions: The developed formulation of a 65 mg double-scored potassium iodide tablet allows the great variability of user needs, from infants to adults with a single pharmaceutical form, which additionally implies logistical benefits in distribution, stock control and appropriate renewal according expiration dates, among the population surrounding nuclear power plants and available to deployed military personnel, in the event of potential nuclear incidents.
Abstract licence: CC BY-NC-ND
Xu Li, Xinlai Wei, Ningning Yang, et al.
ACS Omega, 2024
Lithium iodide is commonly used in the production of batteries and drugs. Currently, the neutralization method is the primary means of producing lithium iodide. This method involves using hydriodic acid as a raw material, adding lithium carbonate or lithium hydroxide, and obtaining lithium iodide through evaporation and concentration. However, hydriodic acid is chemically unstable. Its preparation can lead to explosive accidents and encountering high temperatures generates toxic iodine vapors. These limitations restrict its industrial production. The study evaluates the impact of membrane stack configuration, operating voltage, and initial concentrations and volume ratios of reactants on the production process. Electrodialysis metathesis, characterized by a simpler process flow, lower energy consumption, and environmental benefits, emerges as an effective technique for electrically driven membrane separation in lithium salt production and purification. Under the specific conditions of a C-C-A-C-A-C membrane stack configuration, operating voltage at 25 V, initial potassium iodide concentration at 0.4 mol/L, initial lithium sulfate concentration at 0.2 mol/L, and a 1:1 volume ratio of product liquid to raw material liquid, the method achieves a lithium iodide purity of 98.9% with a production cost of approximately 0.502 $/kg LiI.
Abstract licence: CC BY-NC-ND
Reactions Weekly, 2023
Reactions Weekly, 2023
JDC Emehute, OA Sowande, A Onipede, et al.
African Urology, 2025
Venkatasubramanian Sivakumar, R. Poorna Prakash
SSRN Electronic Journal, 2023
A. Azembayev, Zh. I. Taganov, Y. M. Suiin, et al.
Actual Problems of Theoretical and Clinical Medicine, 2025
Introduction.The growth of antibiotic resistance poses a threat to the global health system and is increasing interest in antimicrobial potentiators. Iodine-based compounds are characterized by low resistance to bacteria and a broad spectrum of action. For their use at the industrial level, it is important to scale up the technology and obtain a stable quality product. Research objective. To conduct the process of scaling up an iodine-based antimicrobial pharmaceutical substance in pilot production conditions, optimize technological parameters and evaluate the quality and stability characteristics of the finished product. Research materials and methods. The study was conducted in the pilot production and laboratories of the JSC « Scientific Center for Anti-Infective Drugs». A substance containing iodine, potassium iodide, starch, polyvinyl alcohol and neutral salts was prepared. Physicochemical analyses (pH, density, quantitative composition), microbiological purity and 12-month stability tests were conducted. Three production batches were prepared and the data were processed. Results. The quality of the finished product met all regulatory requirements: iodine content 8.33–8.39 mg/ml, potassium iodide – 11.73-11.83 mg/ml, pH – 4.24-4.27, density – 1.062-1.063. Microbiological purity indicators fully comply with the requirements. During the study, important technological parameters were analyzed at the main stages of production (raw material measurement, mixing, hydrolysis, obtaining the finished product, quality control, packaging and labeling). Conclusion. The results obtained during the scaling-up of an iodine-based antimicrobial substance are an important scientific and technological base that will allow this substance to be introduced into industrial production. The scaled-up technology allows for the production of high-quality, stable and safe products. As a result of scaling up from the laboratory level to the pilot production site, the critical parameters for the production of an iodine-based antimicrobial potentiator were identified and the technological conditions were optimized. The results obtained will serve as the basis for introducing the pharmaceutical substance into industrial production and will contribute to meeting its growing demand.
Abstract licence: CC BY
Císsara Ramalho Silva Brito, F. E. B. Coelho, E. M. R. Araújo, et al.
OBSERVATÓRIO DE LA ECONOMÍA LATINOAMERICANA, 2025
A great fraction of global iodine production involves the solvent extraction (SX) of iodine from mother liquors. Therefore, a green analytical method for the direct determination of molecular iodine in kerosene was developed and validated using UV–Vis molecular absorption spectrophotometry. Resublimed iodine (≥99.8%) was employed as the analyte, and industrial kerosene (Escaid™ 110) as the solvent. The method was optimized to account for the high reactivity and volatility of iodine, with careful handling, refrigeration, and ultrasonic-assisted dissolution to ensure accurate standard preparation. Validation was performed in accordance with Inmetro, ANVISA, and ASTM E2857 guidelines, assessing selectivity, linearity, working range, detection and quantification limits, recovery, and precision. A wavelength of 521 nm was selected based on the absorption spectrum, and linearity was demonstrated across 0.005–0.55 g·L⁻¹ with R² = 0.998. Recovery values ranged from 97% to 103%, and relative standard deviations were below 5%, confirming both accuracy and precision. The method exhibited negligible interference from potassium iodide, a potential contaminant in industrial processes, such as solvent extraction. Overall, the proposed approach is rapid, cost-effective, and environmentally friendly, providing a reliable tool for monitoring iodine in kerosene during SX processes and supporting process optimization at an industrial scale.
Abstract licence: CC BY-NC
R. Aquaron, F. Delange, P. Marchal, et al.
Cellular and molecular biology, 2002
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Structured knowledge from the free knowledge base
Wikipedia article
used as an antiseptic and a means of treating and preventing iodine deficiency
Read on WikipediaMolecular structure

ATC classifications (Wikidata)
Linked open data from Wikidata (Q28196266), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. Molecular structure images from Wikimedia Commons.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.